TPST
USDTempest Therapeutics Inc. Common Stock
Precio en Tiempo Real
Gráfico de Precios
Métricas Clave
Métricas de Mercado
Apertura
$7.932
Máximo
$7.975
Mínimo
$7.658
Volumen
0.00M
Fundamentos de la Empresa
Capitalización de Mercado
28.3M
Industria
Biotecnología
País
United States
Estadísticas de Negociación
Volumen Promedio
0.06M
Bolsa
NCM
Moneda
USD
Rango de 52 Semanas
Noticias Relacionadas
Tempest Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAP
BRISBANE, Calif., April 21, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (NASDAQ:TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated therapeutics to fight
Tempest Weighs M&A, Analyst Sees A "Broken Story" Despite Phase 2 Liver Cancer Study Success
Tempest Therapeutics hires MTS Health to explore M&A and partnerships after Roche shows limited interest in its liver cancer program.
Scotiabank Downgrades Tempest Therapeutics to Sector Perform, Lowers Price Target to $9
Scotiabank analyst George Farmer downgrades Tempest Therapeutics from Sector Outperform to Sector Perform and lowers the price target from $91 to $9.
HC Wainwright & Co. Downgrades Tempest Therapeutics to Neutral, Maintains Price Target to $16
HC Wainwright & Co. analyst Joseph Pantginis downgrades Tempest Therapeutics from Buy to Neutral and maintains the price target from $16 to $16.
Tempest Announces Plan to Explore Strategic Alternatives to Advance Promising Pipeline of Clinical Oncology Assets and Maximize Stockholder Value
Amezalpat (TPST-1120) is Phase 3-ready: completed FDA and EMA interactions for first-line pivotal study in hepatocellular carcinoma (HCC); global investigator support in placeAwarded both Orphan Drug & Fast Track
Acciones Relacionadas
BCYC
Bicycle Therapeutics plc American Depositary Shares
MGR
Affiliated Managers Group Inc. 5.875% Junior Subordinated Notes due 2059
EEIQ
EpicQuest Education Group International Limited
HUGE
FSD Pharma Inc. Subordinate Voting Shares
PNFPP
Pinnacle Financial Partners Inc. Depositary shares of Pinnacle Financial Partners Inc. each representing a 1/40th Interest in a share of its 6.75% Fixed-Rate Non-Cumulative Perpetual Preferred Stock Series B
Mantente Actualizado
Configura alertas de precio, recibe actualizaciones de análisis de IA y noticias de mercado en tiempo real.